Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Arix Bioscience Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.5yrs

Son yönetim güncellemeleri

Recent updates

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Jan 13

CEO

Arix Bioscience CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tom Davidson	COO & CFO	less than a year	Veri yok	Veri yok
Laura Craig	Investor Relations Officer	less than a year	Veri yok	Veri yok
Tassos Konstantinou	Managing Director	less than a year	Veri yok	Veri yok
Jade Fletcher	Financial Controller	1.1yrs	Veri yok	Veri yok
Felix Breyer	Associate	no data	Veri yok	Veri yok
Roy Bartel-Taverner	Analyst	no data	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: ARIX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Peregrine David Euan Moncreiffe	Independent Non-Executive Chairman	2.8yrs	UK£150.00k	0.58% £ 1.0m
Andrew Smith	Independent Non-Executive Director	1.5yrs	UK£33.00k	Veri yok
Debra Barker	Senior Independent Director	1.5yrs	UK£38.00k	0.040% £ 71.0k

1.5yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ARIX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Arix Bioscience Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Arix Bioscience plc Announces Resignation of Directors

Independent Non-Executive Chairman recently bought UK£69k worth of stock

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Independent Non-Executive Chairman recently bought UK£77k worth of stock

Independent Non-Executive Chairman recently bought UK£217k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought UK£69k worth of stock

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought UK£77k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought UK£217k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Price target increased to UK£2.56

Less than half of directors are independent

Independent Non-Executive Chairman recently bought UK£78k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Price target increased to UK£2.56

Less than half of directors are independent

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Price target increased to UK£2.56

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

New 90-day high: UK£2.22

Executive Chairman recently bought UK£377k worth of stock

Investor sentiment improved over the past week

New 90-day high: UK£1.96

Market bids up stock over the past week

Analysts update estimates

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: UK£1.60

Price target raised to UK£1.71

New 90-day high: UK£1.12

New 90-day high - UK£0.97

Price target raised to UK£1.40

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

CEO

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş